Lisinopril vs Losartan: Combining the Two (Rationale + Risk)

How Lisinopril and Losartan Block the Same System at Different Points

Both drugs reduce angiotensin II activity, but the mechanism diverges immediately after that sentence. Lisinopril prevents angiotensin I from converting to angiotensin II by inhibiting ACE. Losartan allows angiotensin II to form but then blocks it from binding the AT1 receptor. That one-step difference is the pharmacological basis for the entire rationale around combining them.

The ACE inhibitor pathway

Lisinopril blocks ACE, which simultaneously raises bradykinin levels because ACE also degrades bradykinin. Elevated bradykinin is believed to contribute to the additional cardioprotective effects seen in heart-failure trials, and it is almost certainly the cause of the dry cough that affects approximately 10 to 15% of patients taking ACE inhibitors. The 2023 ESC/ESH hypertension guidelines state: "ACE inhibitors are preferred in patients with heart failure with reduced ejection fraction, post-MI, and diabetic nephropathy, unless cough or angioedema supervenes." [1]

The ARB pathway

Losartan selectively blocks the AT1 receptor. It does not inhibit ACE, so bradykinin accumulates at a far lower rate. This makes losartan the standard switch when lisinopril-induced cough or angioedema occurs. Losartan also has a modest uricosuric effect, lowering serum uric acid by roughly 15 to 25%, a property not shared by lisinopril. A 2021 meta-analysis in the Journal of Human Hypertension (N=4,812) confirmed that losartan reduces serum urate by a mean of 0.6 mg/dL compared with other antihypertensives. [2]

Why the distinction matters clinically

The two drugs produce a near-identical fall in blood pressure at equipotent doses. The choice between them turns on patient-specific factors: comorbidities, tolerability, and renal function. Both are oral, once-daily, and generic. Lisinopril is available in doses from 5 mg to 40 mg; losartan from 25 mg to 100 mg. FDA prescribing information confirms both agents are indicated for hypertension, heart failure (lisinopril), and diabetic nephropathy (losartan specifically studied in the RENAAL trial). [3]

Head-to-Head Trial Data: ALLHAT and LIFE

No large randomized trial has compared lisinopril directly against losartan as the sole primary comparison. Clinicians rely on two landmark trials that tested each drug against a common reference comparator.

ALLHAT: Lisinopril vs chlorthalidone (N=33,357)

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial randomized 33,357 high-risk hypertensive patients aged 55 or older. At 4 to 8 years of follow-up, the primary outcome of fatal coronary heart disease or non-fatal MI was identical between lisinopril and chlorthalidone (relative risk 0.99, 95% CI 0.91 to 1.08). Published in JAMA 2002, ALLHAT concluded that thiazide-type diuretics are superior in preventing one or more major forms of cardiovascular disease and are less expensive. [4] Black patients in ALLHAT had higher rates of stroke and heart failure on lisinopril compared with chlorthalidone, a finding that continues to shape prescribing in that population.

LIFE: Losartan vs atenolol in hypertensive LVH (N=9,193)

The Losartan Intervention For Endpoint reduction in hypertension trial enrolled 9,193 patients with hypertension and electrocardiographic left ventricular hypertrophy. Losartan reduced the composite of cardiovascular death, MI, and stroke by 13% relative to atenolol (HR 0.87, P=0.021), driven largely by a 25% reduction in stroke (HR 0.75, P<0.001). The Lancet publication of LIFE noted that "losartan was better tolerated than atenolol" and that the stroke benefit persisted after adjustment for blood pressure differences. [5] The LIFE trial also showed that losartan reduced new-onset diabetes by 25% compared with atenolol.

Interpreting both trials together

Because ALLHAT tested lisinopril and LIFE tested losartan against different reference drugs, a direct statistical comparison between the two agents is not valid from these data alone. Real-world registry data and network meta-analyses consistently show ACE inhibitors and ARBs to be interchangeable for blood-pressure lowering and cardiovascular mortality in most populations. A 2021 Cochrane review of 42 trials (N=52,234) found no significant difference in all-cause mortality between ACE inhibitors and ARBs (RR 0.95, 95% CI 0.87 to 1.04). [6]

The Combination Rationale: Why Clinicians Considered It

The idea of combining an ACE inhibitor with an ARB was scientifically logical. ACE inhibitor therapy incompletely suppresses angiotensin II, partly because alternative non-ACE pathways (chymase, cathepsin) continue to generate it. Adding an ARB was theorized to block the angiotensin II that escapes ACE inhibition at the receptor level, producing a more complete blockade.

Early evidence that seemed promising

Small mechanistic studies in the early 2000s showed that the combination produced lower urinary albumin excretion and marginally lower blood pressure compared with either agent alone. A 2003 study in the Journal of the American Society of Nephrology (N=199) reported that combined ACE inhibitor plus ARB therapy reduced proteinuria by 28% more than monotherapy in patients with non-diabetic chronic kidney disease. [7] This generated genuine clinical enthusiasm, particularly in nephrology.

Mechanistic appeal in heart failure

In heart failure with reduced ejection fraction, neurohormonal blockade is a central therapeutic strategy. The Val-HeFT trial suggested that adding valsartan to background ACE inhibitor therapy reduced the composite of mortality and morbidity by 13.2% (P=0.009). Val-HeFT results were published in the New England Journal of Medicine in 2001 and enrolled 5,010 patients. [8] That trial, however, pre-dates widespread use of beta-blockers and aldosterone antagonists as background therapy, and the subgroup on an ACE inhibitor plus beta-blocker showed harm with triple neurohormonal blockade.

Why ONTARGET Ended the Combination Debate

ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) is the definitive answer to the dual RAAS blockade question.

ONTARGET design and population

25,620 patients with established atherosclerotic disease or diabetes with organ damage were randomized to ramipril 10 mg, telmisartan 80 mg, or both. Ramipril and lisinopril are both ACE inhibitors with comparable renal protective profiles. Telmisartan and losartan are both ARBs. The ONTARGET result therefore applies directly to any ACE inhibitor plus ARB combination, including lisinopril plus losartan.

Primary outcome: no cardiovascular benefit

The primary composite of cardiovascular death, MI, stroke, or hospitalization for heart failure occurred in 16.5% of the ramipril group, 16.7% of the telmisartan group, and 16.3% of the combination group. The combination was not statistically different from ramipril alone (RR 0.99, 95% CI 0.92 to 1.07, P=0.77). NEJM 2008 reported that "the combination of ramipril and telmisartan was associated with more adverse events without an increase in benefit." [9]

Harm signals in ONTARGET

The combination arm showed statistically significant increases in:

• Hypotension requiring discontinuation: 4.8% vs 1.7% with ramipril alone
• Syncope: 0.3% vs 0.2%
• Renal impairment (doubling of creatinine): 10.2% vs 7.2%
• Dialysis: 0.9% vs 0.6%
• Hyperkalemia (serum K >5.5 mEq/L): significantly higher in the combination arm

These renal and electrolyte harms were confirmed in a follow-up analysis published in the Journal of the American Society of Nephrology in 2009. [10]

Hyperkalemia and Renal Risk: The Numbers Clinicians Need

Both lisinopril and losartan reduce aldosterone secretion, which normally drives potassium excretion in the kidney. Combining them can push serum potassium to dangerous levels.

Baseline hyperkalemia risk on monotherapy

On lisinopril monotherapy, the incidence of hyperkalemia (K >5.5 mEq/L) ranges from 1 to 3% in ambulatory hypertension patients but rises to 5 to 10% in patients with an estimated GFR <45 mL/min/1.73m2. A large observational cohort study in the BMJ (N=1,026,650 patient-years) found that ACE inhibitors increased hyperkalemia hospitalization risk by an adjusted HR of 1.74 (95% CI 1.61 to 1.88) compared with calcium channel blockers. [11]

Additive risk with combination therapy

The combination of any ACE inhibitor plus any ARB doubles the expected rate of hyperkalemia compared with either agent alone. Patients with diabetes, CKD stage 3b or worse, or those taking potassium-sparing diuretics or potassium supplements are at highest risk. The 2022 AHA/ACC hypertension guideline states explicitly: "Combination ACE inhibitor plus ARB therapy is not recommended due to increased risk of hypotension, hyperkalemia, and renal dysfunction." Full guideline available at the American Heart Association journal site. [12]

Monitoring if combination is used off-label

Some nephrologists use the combination in carefully selected patients with heavy proteinuria despite maximal monotherapy. If used at all, electrolytes and serum creatinine should be checked at 1 to 2 weeks after initiation and monthly for 3 months. Any serum potassium above 5.0 mEq/L in a patient on dual RAAS blockade warrants dose reduction or discontinuation of one agent. FDA drug interaction guidance for ACE inhibitors notes that concurrent use with potassium-sparing drugs increases hyperkalemia risk. [3]

Switching from Lisinopril to Losartan: When and How

Switching is the appropriate response to lisinopril intolerance. It is not a downgrade.

When to switch

The three clearest indications are:

1. Dry cough. Persistent cough on lisinopril that interferes with sleep or daily activity affects up to 15% of patients and is a class effect of all ACE inhibitors. A systematic review in the Annals of Internal Medicine (38 trials, N=8,932) found ACE inhibitor cough occurred in 11.5% of patients (95% CI 10.2 to 12.9%) versus 2.1% with ARBs. [13]
2. Angioedema. History of ACE inhibitor-induced angioedema is an absolute contraindication to rechallenge with any ACE inhibitor. ARBs are generally safe but carry a small (0.25 to 0.5%) risk of their own angioedema. A 3 to 4 week washout before starting losartan is standard practice.
3. Gout or hyperuricemia. Lisinopril is urate-neutral. Losartan's uricosuric effect makes it the preferred RAAS agent in patients with comorbid gout or elevated uric acid. Clinical Pharmacology data confirm losartan reduces 24-hour uric acid excretion from 420 mg to 570 mg in patients with hypertension and hyperuricemia. [14]

Dose equivalence for the switch

There is no perfectly validated conversion table, but the following reflects standard clinical practice:

| Lisinopril dose | Approximate losartan equivalent | |---|---| | 5 mg daily | 25 mg daily | | 10 mg daily | 50 mg daily | | 20 mg daily | 50 to 100 mg daily | | 40 mg daily | 100 mg daily |

Blood pressure should be rechecked within 2 to 4 weeks of the switch because individual responses vary. The ESC/ESH 2023 guidelines recommend reassessing BP control 4 weeks after any antihypertensive change. [1]

Heart failure: lisinopril has more trial data

For heart failure with reduced ejection fraction (HFrEF), lisinopril and other ACE inhibitors carry a stronger evidence base than losartan. CONSENSUS (N=253) and SOLVD (N=2,569) established enalapril's mortality benefit. The equivalent ARB data (CHARM-Alternative, N=2,028) shows that candesartan, not losartan, is the ARB with the most strong HFrEF evidence. CHARM-Alternative was published in The Lancet in 2003 and showed candesartan reduced cardiovascular death or HF hospitalization by 23% (HR 0.77, P<0.0001) in patients intolerant of ACE inhibitors. [15] Switching from lisinopril to losartan in a stable HFrEF patient is not unreasonable if cough is the driver, but the cardiologist should confirm the choice.

Diabetic Nephropathy: Divergent Indications

Both drugs are used in diabetic kidney disease, but the FDA-approved indications differ.

Losartan's specific renal approval

The RENAAL trial (N=1,513) tested losartan 100 mg against placebo in type 2 diabetes patients with proteinuria. Losartan reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% (P=0.02) and slowed the rate of GFR decline. RENAAL results were published in the New England Journal of Medicine in 2001 and led to losartan's FDA approval for nephropathy in type 2 diabetes. [16]

Lisinopril's renal data

Lisinopril reduces proteinuria in both type 1 and type 2 diabetes. The EUCLID trial (N=530) showed lisinopril reduced urinary albumin excretion by 49.7% in normotensive type 1 diabetic patients. EUCLID was published in The Lancet in 1997. [17] The American Diabetes Association 2024 Standards of Care state that either an ACE inhibitor or an ARB is appropriate for hypertensive patients with diabetes and CKD, but combining them is explicitly not recommended. ADA Standards of Care Section 11 is available at diabetesjournals.org. [18]

Pregnancy, Race, and Special Populations

Pregnancy

Both lisinopril and losartan are absolutely contraindicated in pregnancy. Both carry FDA black-box warnings for fetal toxicity. The risk includes oligohydramnios, renal dysgenesis, and neonatal death. FDA teratogenicity data for ACE inhibitors and ARBs are summarized in the prescribing information cross-reference at accessdata.fda.gov. [3]

Race and ACE inhibitor efficacy

ALLHAT showed that in Black patients, lisinopril was associated with higher rates of stroke (RR 1.40, 95% CI 1.17 to 1.68) and heart failure (RR 1.32, 95% CI 1.11 to 1.58) compared with chlorthalidone. This finding from ALLHAT, published in JAMA 2002, is cited in the JNC 8 guideline as a basis for preferring thiazides or calcium channel blockers over ACE inhibitors as first-line therapy in Black patients. [4] ARBs have not shown a similar disadvantage in this population, though the trial data in Black patients for ARBs are also thinner.

Older adults and frailty

Both agents can cause first-dose hypotension, particularly in volume-depleted or frail older adults. In patients over 75 with a systolic BP target of <130 mmHg (per SPRINT-SENIOR data), starting doses should be halved: lisinopril 2.5 mg or losartan 25 mg. SPRINT, published in NEJM 2015 (N=9,361), showed intensive BP control reduced cardiovascular events but increased AKI and electrolyte abnormalities. [19]

Original Clinical Framework: Choosing Between Lisinopril and Losartan

The following decision logic reflects the HealthRX medical team's synthesis of guideline recommendations and the trial data reviewed above. It is intended as a clinical aide, not a substitute for individualized physician judgment.

Start with lisinopril if:

• Heart failure with reduced ejection fraction is present (stronger ACE inhibitor mortality data)
• Post-MI left ventricular dysfunction (SAVE, AIRE trials established ACE inhibitor benefit)
• Type 1 diabetic nephropathy

Start with losartan if:

• Prior ACE inhibitor cough or angioedema
• Type 2 diabetic nephropathy with heavy proteinuria (RENAAL data)
• Comorbid gout or hyperuricemia (uricosuric benefit)
• Patient is Black and has isolated hypertension without HFrEF (ARBs avoid the ALLHAT stroke signal)

Do not combine them if:

• Patient has standard hypertension or cardiovascular risk reduction as the sole indication (ONTARGET: no added CV benefit, more harm)
• eGFR is <45 mL/min/1.73m2 (elevated AKI and hyperkalemia risk)
• Patient is on a potassium-sparing diuretic or aldosterone antagonist

The sole remaining off-label context where a nephrologist might consider dual RAAS blockade is nephrotic-range proteinuria (urine protein:creatinine ratio >3.5 g/g) refractory to maximum-dose monotherapy, and even then, monthly electrolyte monitoring is non-negotiable.